Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Pertl, L; Steinwender, G; Mayer, C; Hausberger, S; Pöschl, EM; Wackernagel, W; Wedrich, A; El-Shabrawi, Y; Haas, A.
A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.
PLoS One. 2015; 10(6): e0129383-e0129383.
Doi: 10.1371/journal.pone.0129383
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Haas Anton
- Posch-Pertl Laura
- Co-Autor*innen der Med Uni Graz
- El-Shabrawi Yosuf
- Malle Eva Maria Birgit
- Mayer-Xanthaki Christoph Fidel
- Pinter-Hausberger Silke
- Steinwender Gernot
- Wackernagel Werner
- Wedrich Andreas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Laser photocoagulation is the current gold standard treatment for proliferative retinopathy of prematurity (ROP). However, it permanently reduces the visual field and might induce myopia. Vascular endothelial growth factor (VEGF) inhibitors for the treatment of ROP may enable continuing vascularization of the retina, potentially allowing the preservation of the visual field. However, for their use in infants concern remains. This meta-analysis explores the safety of VEGF inhibitors. The Ovid Interface was used to perform a systematic review of the literature in the databases PubMed, EMBASE and the Cochrane Library. This meta-analysis included 24 original reports (including 1.457 eyes) on VEGF inhibitor treatment for ROP. The trials were solely observational except for one randomized and two case-control studies. We estimated a 6-month risk of retreatment per eye of 2.8%, and a 6-month risk of ocular complication without the need of retreatment of 1.6% per eye. Systemic complications were only reported as isolated incidents. VEGF inhibitors seem to be associated with low recurrence rates and ocular complication rates. They may have the benefit of potentially allowing the preservation of visual field and lower rates of myopia. Due to the lack of data, the risk of systemic side effects cannot be assessed.
- Find related publications in this database (using NLM MeSH Indexing)
- Angiogenesis Inhibitors - adverse effects
- Humans -
- Retina - drug effects
- Retinopathy of Prematurity - drug therapy
- Vascular Endothelial Growth Factor A - antagonists & inhibitors